CRSP

In the past six months (April - October 2026), CRISPR Therapeutics AG's stock price increased by 3.17%, though it declined by 31.38% over the last year. Key events included business updates and financial results reported on May 4 and August 3, 2026. On August 28, 2026, the company presented positive Phase 1a data for CTX310 at the ESC Congress 2026, demonstrating deep and durable ANGPTL3 editing and lipid lowering. CRISPR Therapeutics also presented at the Morgan Stanley 24th Annual Global Healthcare Conference on September 8, 2026. News on September 29, 2026, highlighted two key catalysts expected by year-end. In October, the company announced a poster presentation of clinical data on zugocabtagene geleucel in autoimmune disease at ACR Convergence 2026, and Cathie Wood listed CRSP among her top bets. On October 8, 2026, CRISPR Therapeutics announced late-breaking data presentation for CTX310 at AHA Scientific Sessions 2026. On October 9, 2026, H.C. Wainwright and Citizens reiterated 'Buy' and 'Market Outperform' ratings, respectively, both with an $80 price target, citing updated CTX310 data.